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Abstract. – OBJECTIVE: Metabolic syndrome 
(MetS) is defined as a spectrum of conditions 
associated with an increased risk of developing 
CVD and type 2 diabetes.
MetS include: hyperglycemia, hypertension, 
visceral obesity, dyslipidemia with elevated val-
ues of triglycerides (TG) and low levels of HDL.
The aim of this review is to provide current 
knowledge of the relationship between MetS, its 
components and peri-implant diseases.
MATERIALS AND METHODS: An electronic 
literature search was conducted in the English 
language in several databases. 
The Newcastle-Ottawa Scale was used for 
quality assessment of cohort and cross-sec-
tional studies; while systematic reviews were 
evaluated through AMSTAR; results were re-
ported according to the PRISMA Statement.
RESULTS: A total of 272 records were iden-
tified through database searching, six studies 
were included for qualitative analysis. No study 
directly related to MetS was found, there was 
inconsistent and controversial evidence regard-
ing association with cardiovascular disease. A 
higher risk of peri-implantitis was detected in 
people with hyperglycemia.
CONCLUSIONS: Future research should be 
orientated in assessing the risk of peri-implant 
diseases, evaluating patient’s therapeutic re-
sponse, analyzing directionality of the relation-
ship between MetS, its components and biolog-
ic implant complications.
Key Words
Peri-implantitis, Mucositis, Peri-implant diseases, 
Metabolic syndrome, Cardiovascular disease, Hyper-
glycemia.
Introduction
High life expectancy and demographic trends, 
as well as widespread diffusion and reliability of 
modern implant dentistry, are all factors that have 
contributed to the increased number of dental 
implants in elderly patients (age > 65 years)1-3. 
Compton et al2, in 2017, retrospectively re-
viewed a cohort of 245 geriatric patients and 
reported an implant survival rate of 92.9%, with 
marginal bone loss present in 23.3% of implants.
Schimmel et al3, in 2017, concluded that place-
ment of dental implants in elderly patients had 
become routine practice and clinicians should 
carefully take into account coexisting systemic 
risk factors.
Geriatric patients usually report, in their med-
ical history, several comorbidities, with the most 
common ones as cardiovascular disease (CVD), 
hypertension, diabetes mellitus, hyperglycemia, 
osteoporosis and consequent assumption of an-
ti-resorptive medications, dyslipidaemia and tem-
poromandibular disorders2-7. 
Several authors8-11 referred a positive correla-
tion and a direct relationship between periodon-
titis and systemic diseases over the years: CVD, 
hypertension, dyslipidaemia and mostly diabetes 
mellitus and hyperglycemia.
Shimazaki et al12 and D’Aiuto et al13 reported, 
for the first time, a correlation between meta-
bolic syndrome and periodontal disease in two 
cross-sectional studies. 
Overview of the Metabolic Syndrome
The Metabolic syndrome (MetS) is defined 
as a spectrum of conditions associated with an 
increased risk of developing CVD and type II 
diabetes14,15. 
MetS include: hyperglycemia, hypertension, 
visceral obesity, dyslipidemia with elevated val-
ues of triglycerides (TG) and low levels of HDL.
Prevalence of metabolic syndrome has been 
reported steadily rising over last decade: ac-
cording to the most recent survey of the Na-
tional Health and Nutrition Examination Survey 
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(NHANES) its prevalence is estimated around 
34.7% in the American population, while in Eu-
rope is considered to be around 30% in elderly 
population16.
Over the years, several diagnostic criteria have 
been suggested by different health organizations: 
National Cholesterol Education Program’s Adult 
Treatment Panel III (NCEP ATP III), the Inter-
national Diabetes Federation (IDF), the World 
Health Organization (WHO) and the American 
Heart Association and National Hearth, Lung, 
and Blood Institute (AHA/ NHLBI)17-20.  
In a recent systematic review, Nibali et al21 
suggested that evaluation of periodontal param-
eters should become part of routine diagnostic 
procedures for patients affected by metabolic 
syndrome. 
Authors22,23,24 highlighted how the prevalence 
of periodontal disease in patients affected by 
MetS was almost double, compared to those 
without Mets (OR=1.7-2.1).
Systemic oxidative stress and up-regulation 
of inflammatory cytokines (IL-1, IL-6, TNF-α) 
were hypothesized as a possible cause of reduced 
insulin sensitivity, a key aspect in MetS develop-
ment22-24.
However, in a recent critical review, the 
literature on the possible association between 
periodontitis and metabolic syndrome has been 
judged as “biased”, due to the heterogeneity of 
cross-sectional studies21.
Overview of Peri-Implantitis
The massive use of dental implants in EU Pop-
ulation over the last decades has also developed 
a combination of “man-made” diseases known as 
“peri-implant diseases”25.
Peri-implantitis has been defined as a chronic 
inflammatory lesion, characterized by peri-im-
plant bone loss, bleeding at probing and suppu-
ration25,26.
Mucositis was defined as a plaque-related 
inflammatory soft tissue infiltrate with no con-
comitant loss of supporting bone27.
Sanz and Chapple28 highlighted how lack of 
consensus on definition and diagnosis may affect 
peri-implantitis prevalence.
They founded eight different definitions of 
peri-implants, based on the combination of sever-
al marginal bone loss (MBL) values and probing 
pocket depth (PPD) considered as thresholds.
Its prevalence, therefore, remains controver-
sial and relatively unknown, depending mostly 
on study design and population: Derks and To-
masi reported 43% of dental implants affected 
by mucositis and 22% by peri-implantitis after 
a mean follow-up of 9 years in a Swedish pop-
ulation29.
Hence, peri-implantitis represent an emerging 
disease and, like periodontitis, occurs mainly as 
a result of an overwhelming bacterial insult and 
subsequent host immune response, with a spon-
taneous progression if left untreated30-32. 
In particular, several authors33,34 reported that 
bacterial species associated with periodontitis 
and peri-implantitis are similar, including main-
ly Gram-negative anaerobes such as Porphy-
romonas gingivalis, Prevotella intermedia and 
Aggregatibacter actinomycetemcomitans (Aa). 
Furthermore, pro-inflammatory cytokines 
(IL-1, IL-6, IL-8 and TNF- α) are up-regulated 
in peri-implantitis35. 
According to Salvi et al36, even if peri-implan-
titis and periodontitis share similarities in patho-
genic mechanisms and clinical features, they 
have to be considered as different histopathologic 
entities.
History of periodontitis has been considered 
as a risk factor for implant patients. However, 
a direct relationship between implant loss and 
periodontal disease has never been demonstrated.
Over the years, just a few papers have focused 
their attention on coexisting medical conditions 
and peri-implantitis1,5. 
The aim of this review is to provide current 
knowledge of the relationship between MetS, its 
components and peri-implant diseases.
Material and Methods
This systematic review was conducted in ac-
cordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRIS-
MA)37.
The protocol of this systematic review was 
developed “a priori” following initial discussion 
between members of the research team.
Focused Question
Investigators conducted a literature review in 
accordance with the following focused question: 
Are patients affected by metabolic syndrome 
(MetS) or one/more of its components present-
ing a higher occurrence of peri-implant diseases 
compared to healthy subjects?
 • Population: Patients with osseointegrated den-
tal implants.
 • Exposure: patients affected by metabolic syn-
drome (MetS) or one/more of its components 
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(Hypertension, cardiovascular disease, hyper-
glycemia, diabetes, dyslipidaemia, obesity).
 • Comparison: patients in good general health.
 • Outcome: implant-related biologic complica-
tions (mucositis, peri-implantitis or peri-im-
plant bone loss). 
Search Strategy
An electronic literature search was conducted 
independently by two authors (PP, DR) for reports 
published up to 1st June 2017 in English language 
in several databases: Pubmed library, Web of 
Science (Thomson Reuters), SciVerse (Elsevier), 
MEDLINE (OVID) and through The Cochrane 
Database of Systematic Reviews (CDSR).
The following search strategy was performed: 
(diseases OR conditions OR pathologies OR car-
diovascular OR diabetes OR obesity OR meta-
bolic syndrome
OR hyperglycemia OR hypertension OR dys-
lipidaemia) AND (peri-implantitis OR peri-im-
plant inflammation OR peri-implant disease OR 
peri-implant infection OR peri-implant bone loss 
OR peri-implant mucositis OR mucositis) AND 
(risk factors).
Study Selection
Studies were included if they presented data 
on patients with a diagnosis of peri-implantitis 
or peri-implant mucositis, affected by metabolic 
syndrome or one/more of its components.
Systematic reviews of human in vivo stud-
ies, prospective and retrospective cohort studies, 
case-control studies, cross-sectional surveys and 
case series were included in this literature review.
Studies were selected based on the following 
inclusion criteria:
 • Human trials with at least 10 subjects.
 • Implants with at least 1 year follow-up since 
delivery of definitive prosthetic restoration.
 • Studies published in English.
Outcome Definitions 
Only studies reporting definitions of peri-im-
plantitis and peri-implant mucositis in accor-
dance with the European peri-implant disease 
case definitions28 were included in this review.
The peri-implantitis was defined as presence 
of bleeding on probing and/or suppuration to-
gether with evidence of concomitant ≥ 2 mm 
radiographic marginal bone loss.
Peri-implant mucositis was defined as evi-
dence of bleeding on probing and/or suppuration 
without concomitant marginal bone loss.
Peri-implant bone loss was defined as detect-
able radiographic bone loss without evidence of 
bleeding on probing and/or suppuration.
Metabolic syndrome is considered as a spec-
trum of conditions including hyperglycemia, hy-
pertension, visceral obesity, dyslipidaemia with 
elevated values of triglycerides (TG) and low 
levels of HDL.
Presence of three or more of the following 
diagnostic criteria, as defined by NCEP ATP III, 
was needed to establish a diagnosis of MetS:
 • Waist circumference >102 cm (M) or >88 cm 
(F).
 • Triglyceridemia > 150 mg/dL.
 • HDL-cholesterol <40 mg/dL (M) or < 50 mg/
dL (F).
 • Blood pressure > 130/85 mmHg.
 • Fasting glucose > 110 mg/dL.
Studies reporting data on one or more of the 
following components of MetS and peri-implant 
diseases were included in this review:
• Hypertension.
• Cardiovascular disease: defined as arterial hy-
pertension and/or cardiac and/or peripheral 
vascular disease; with concomitant drug ther-
apy, including anticoagulants and/or calcium 
channel blockers/angiotensin-converting en-
zyme inhibitors/nitrosamines.
 • Obesity 
 • Dyslipidemia.
 • Hyperglycemia .
 • Diabetes mellitus.
Quality and Risk of Bias Assessment
The quality of each cohort and case-control 
study was evaluated according to NewCastle-Ot-
tawa scale (NOS) for Assessing the Quality of 
Non-randomized Studies38. 
The NOS include three sections: selection 
(four items), comparability
(two items) and outcome (three items). A 
maximum of one star for each item can be award-
ed within the selection and outcome categories, 
while two stars can be given for comparability.
Evaluation of cross-sectional studies was 
made according to NOS modified by Borgnakke 
et al39, including three sections: selection (four 
items), comparability (two items) and outcome 
(one item), with a maximum of one star for each 
item, excluding comparability with two stars.
The MeaSurement Tool to Assess Systematic 
Reviews (AMSTAR), an 11-items questionnaire, 
was performed to assess systematic reviews in-
cluded40. 
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Data extraction and analysis 
Two reviewers (PP, DR), independently from 
each other, extracted pertinent data (year; study 
design; systemic condition; biologic implant com-
plication; number of patients; number of im-
plants; outcome) from selected studies in order 
to perform a meta-analysis.
However, due to heterogeneity of study de-
signs and outcome variables, data were reported 
narratively and, therefore, no meta-analysis was 
performed. 
Results
A total of 272 records were identified through 
database searching.
After removal of duplicates, forty-five stud-
ies were selected for title and abstract analyses, 
with 19 articles considered for detailed screening 
(Chart I).
Six studies were included for qualitative anal-
ysis: a systematic review with meta-analysis, 
three cohort studies (one prospective and two 
retrospectives) and two cross-sectional studies 
(Table I).
Reasons for exclusion are detailed in Chart I. 
The kappa agreement between reviewers was 0.85.
No study related to metabolic syndrome was 
identified and, as for its components: five articles 
reported data on hypertension and cardiovascular 
disease, whereas the systematic review included 
twelve studies on hyperglycemia and diabetes.
Two articles41,42 both reported data on CVD 
and diabetes and were included in the systematic 
review43.
As for the qualitative analysis, according to 
AMSTAR, risk of bias was very low for Monje 
et al43; while the mean NOS score was 5 for 
cross-sectional studies and 7.33 for cohort studies 
(Table II, Table III).
Cardiovascular Disease
In a retrospective study41, authors found a 
history of CVD in 27.3% of individuals with 
peri-implantitis, while CVD was present just in 
3% of individuals in the implant health/peri-im-
plant mucositis group.
They concluded that a history of CVD had a 
high likelihood of comorbidity with peri-implanti-
tis, expressing an odds ratio (OR) of 8.7 (95% CI: 
1.9, 40.3 p < 0.006).
Chart 1. I PRISMA “search and selection” 
flow-chart.
P. Papi, C. Letizia, A. Pilloni, L. Petramala, V. Saraceno, D. Rosella, G. Pompa
870
Table I. Characteristics of the studies included in the qualitative syntheses.  
ABL = Additional bone loss; CI = Confidence interval; CVD = Cardiovascular disease; DM = Diabetes; NR = not reported; OR = 
Odd ratio; RR = Risk ratio
Study Study  Systemic Implant- No. of No. of Outcome  
 Design  condition  related  patients  implants 
    biologic
    complication   
Koldsland et al44 Cross-sectional Cardiovascular Peri- 109 374 No statistical
  study  disease  implantitis CVD: 17 NR  association
   Peri-implant    reported
    bone loss 
   Mucositis 
De Souza et al45 Retrospective  Hypertension Peri-implant 193 722 ABL= 63/165
  cohort study   bone loss CVD: 35 165  implants (38.2%)
      p-value: 0.702
Renvert et al41 Retrospective  Cardiovascular Peri-implantitis 172 NR Peri-implantitis
  cross-sectional   disease Mucositis CVD: 47 NR OR= 8.7
  study      (95% CI: 1.9, 40.3) 
Krennmair et al46 Prospective  Cardiovascular Peri-implant 44 176 OR= 5.72
  cohort study  disease  bone loss CVD: 19 NR  (95% CI: 1.280-
       20.908).
Dalago et al42  Cross-sectional Cardiovascular Peri-implantitis 183 938 8/61 implants
  study  disease  CVD: 11  61 p-value: 0.012
Monje et al43 Systematic  Hyperglicemia Peri-implantitis 1955 2892 Peri-implantitis 
  review with  Diabetes Mucositis DM: 480 NR RR=1.46
  meta-analysis      (95% CI: 1.21-1.77) 
       OR = 1.89; (95% CI: 
       1.31-2.46)
      Mucositis
      RR = 0.92
       (95% CI: 0.72-1.16)
      OR = 1.06
       (95% CI: 0.84-1.27)
Table II. NOS for quality assessment of cohort studies.
ABL = Additional bone loss; CI = Confidence interval; CVD = Cardiovascular disease; DM = Diabetes; NR = not reported; OR = 
Odd ratio; RR = Risk ratio
Study Selection    Compa- Outcome   Total
  (Max. 4 Stars)    rability  (Max. 3 Stars)
      (Max. 2 
      Stars)  
 Represen- Selection Ascerta- Demonst- Compara- Assessment Was  Adequacy of
  tativeness  of non  inment  ration  bility of  of  follow-up  follow-up 
  of the   exposed  of  that  cohorts  outcome  long  of cohorts 
  exposed   cohort  exposure  outcome   on the  (Max 1  enough for  (Max 1
  cohort   (Max 1  (Max 1  was not   basis  Star)  outcomes  Star)
  (Max 1   Star)  Star)  present   of the   to occur 
  Star)    at start   design or   (Max 1 
     of study  analysis   Star) 
     (Max 1   (Max 2   
     Star)  Stars)      
De Souza  * * *  * * * * 7
 et al45
Renvert *  *  * * * * 6
 et al41
Krennmair * * * * ** * * * 9
 et al46
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Koldsland et al44 evaluated, in a cross-sec-
tional study, the association between selected 
risk factors and peri-implantitis in a population 
of 109 patients.
Fourteen individuals reported history of CVD 
and results of multi-level regression analysis 
showed no statistically significant association 
between variable and peri-implantitis.
De Souza et al45 investigated a cohort of 193 
patients retrospectively to evaluate influence of lo-
cal and systemic factors on peri-implant bone loss. 
Thirty-nine patients presented a diagnosis of 
CVD (35 hypertension and 4 cardiac diseases); 
however, no systemic factor showed influence on 
peri-implant bone loss.
Krenmair et al46 conducted a prospective cohort 
study with 3 years follow-up, evaluating peri-im-
plant bone loss in patients with fully edentulous 
mandibles rehabilitated with four dental implants. 
Their results highlighted that subjects affected 
by CVD (n=19/44) showed statistically significant 
increased peri-implant bone loss levels, express-
ing an OR of 5.72 (95% CI: 1.280-20.908).
Dalago et al42, in a cross-sectional study, col-
lected data on 183 patients and 916 dental im-
plants: according to the authors, heart disorders 
showed no correlation with peri-implantitis.  
Hyperglicemia
In a recent systematic review with meta-analy-
sis, Monje et al43 evaluated current literature avail-
able regarding the association between diabetes 
mellitus/ hyperglycemia and peri-implant diseases.
After electronic literature searching, twelve 
articles were considered eligible for qualitative 
analysis, while just seven of them for quantitative.
Meta-analysis reported a 50% higher risk of 
detecting peri-implantitis in subjects with dia-
betes/hyperglycemia compared to non-diabetes 
patients (RR = 1.46; 95% CI: 1.21-1.77 and OR = 
1.89; 95% CI:1.31-2.46; p < .001).
Diabetes patients no-smokers showed a 3.39 
higher risk for peri-implantitis compared to nor-
moglycaemia subjects, therefore suggesting that 
smoking, contrary to what hypothesized in lit-
erature, had no leading role in development of 
peri-implant diseases compared to diabetes.
Dyslipidemia
No studies evaluating correlation between 
peri-implant diseases and dyslipidemia were 
found in literature.
Discussion
To the best of the authors’ knowledge, this is 
the first systematic review to report data regard-
ing MetS, its components and their relationship 
with peri-implant diseases.
Therefore, there are no previous reviews to 
which our findings can be compared.
MetS is a spectrum of conditions with a five-
fold increased risk of diabetes and two-fold risk 
of developing CVD14,15.
In the literature, only a narrative review au-
thored by Darby et al47 in 2015 mentioned meta-
bolic syndrome as a possible key factor in man-
agement of periodontal elderly patients.  
According to the authors, a multidisciplinary 
team approach with medical colleagues to best 
manage these patients should be implemented. 
Table III. NOS for quality assessment of cross-sectional studies.
Study Selection    Compra- Outcome  Total
  (Max. 4 Stars)    bility  (Max. 1
       Stars)
 Representa- Selection Ascertain- Demonstra- Comparability Assessment 
  tiveness of   of non  ment of  tion that  of cohorts on  of outcome  
  the exposed   exposed  exposure  outcome  the basis of   (Max 1 Star)  
  subjects   subjects  (Max 1  was not  the design or 
  (Max 1 Star)  (Max 1 Star)  Star)  present   analysis 
     at start   (Max 2 Stars)
     of study
     (Max 1 Star) 
Koldsland * * *  * * 5
 et al44 
Dalago * * *  * * 5
 et al42
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Over the years, just a few authors have inves-
tigated the possible comorbidity between cardio-
vascular disease (CVD) and peri-implant diseases.
In two different studies, Alsaadi et al48,49 eval-
uated association between local and systemic fac-
tors and early and late implant failure, reporting 
no statistically significant correlation with CVD.
Lachmann et al50, in a cross-sectional study, eval-
uated clinically and microbiologically an unselected 
population of seventy-four implant recall patients. 
CVD was found out in twenty individuals, 
with hypertension (n=14) being the most common 
condition diagnosed.
All the positive subjects for Prevotella inter-
media (Pi) (n=6/74) exhibited CVD. Therefore, the 
cohort of cardiovascular disease patients showed 
statistically significant higher mean Pi load.
These results were not judged “surprising” by 
authors, as an association between Pi and other 
that bacterial species linked with periodontitis 
was reported by several authors51-53. 
However, for the first time, this association 
between periodontal pathogens and CVD was 
reported in the peri-implant sulcus.
Three articles included in our review showed no 
possible correlation with CVD, whereas two of them41,46 
reported an increased risk of developing peri-implant 
diseases, with OR ranging from 5.72 to 8.7.
According to Krennmair et al46, osseointe-
gration may be compromised and marginal bone 
loss improved, in CVD patients, by reduction of 
oxygen tension and nutrient supply caused by 
lower blood flow54,55. 
More data is available on literature regarding 
possible links between hyperglycemia and dia-
betes and biologic and mechanical complications 
related to dental implants39,56,57. 
According to several authors, elevated glycemic 
values seem to be associated with higher rates of 
peri-implantitis and peri-implant bone loss43,56. 
Peri-implantitis, as well as periodontitis, is 
considered sensitive to factors inducing tissue 
inflammation (smoking, poor plaque control, hy-
perglycemia), which can usually be found in the 
same population58-61. 
According to Monje et al43, non-smokers 
patients affected by hyperglycemia reported a 
threefold higher risk of peri-implantitis, hence 
smoking was not a key factor in enhancing ef-
fects of hyperglycemia.
Limitations 
The aim of this review was to assess, in a 
systematic manner, metabolic syndrome and its 
components as possible risk factors for peri-im-
plant diseases.
Main limitations and source of bias were 
represented by absence of randomized clinical 
trials and by the retrospective and cross-sectional 
design of almost all studies included.
No study directly related to MetS was found; 
therefore, only articles related to its components 
were selected.
Only two articles reported data on hyperten-
sion, while the other three referred to the broader 
category of cardiovascular disease, which include 
many other cardiac conditions.
Different coexisting medical diseases and/or 
risk factors (e.g., smoking) were observed in the 
same patient, then identification of the proper 
condition related to biologic implant complica-
tions could be biased.
On the contrary, MetS represent a spectrum 
of different conditions and elderly subjects are 
usually affected by multiple medical disorders.
History of periodontitis was not analyzed 
by all studies: its relationship with peri-implant 
diseases is still unknown, even if they share 
similarities in aetiology and pathogenic mech-
anisms.
MetS and periodontitis have recently been 
correlated by several cross-sectional studies; 
however, the body of scientific evidence is still 
immature.
On the contrary, it is reported in literature that 
periodontal disease is a condition that increases 
risk of CVD62 and may negatively affect glycemic 
control of diabetic patients57,63.
Another important limitation is represented 
by lack of standard, globally accepted definitions 
of peri-implant diseases, which may influence 
their prevalence.
Conclusions
The following conclusions can cautiously be 
drawn:
 • There are no articles in literature analyz-
ing possible correlation between Mets and 
peri-implant diseases.
• There is inconsistent and controversial evi-
dence regarding association of cardiovascular 
disease and biologic implant complications.
• A higher risk of peri-implantitis was detected 
in people with hyperglycemia compared to 
those with normal blood glucose levels.
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Future research should be orientated in con-
ducting longitudinal studies, evaluating patients 
affected by metabolic syndrome rehabilitated 
with dental implants.
Goals should be to assess risk of peri-implant 
diseases and to evaluate patient’s therapeutic 
response, analyzing directionality of the relation-
ship between MetS, its components and biologic 
implant complications.
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